OBJECTIVE: The authors examined the effectiveness of virtual reality exposure augmented with D-cycloserine or alprazolam, compared with placebo, in reducing posttraumatic stress disorder (PTSD) due to military trauma. METHOD: After an introductory session, five sessions of virtual reality exposure were augmented with D-cycloserine (50 mg) or alprazolam (0.25 mg) in a double-blind, placebo-controlled randomized clinical trial for 156 Iraq and Afghanistan war veterans with PTSD. RESULTS:PTSD symptoms significantly improved from pre- to posttreatment across all conditions and were maintained at 3, 6, and 12 months. There were no overall differences in symptoms between D-cycloserine and placebo at any time. Alprazolam and placebo differed significantly on the Clinician-Administered PTSD Scale score at posttreatment and PTSD diagnosis at 3 months posttreatment; the alprazolam group showed a higher rate of PTSD (82.8%) than the placebo group (47.8%). Between-session extinction learning was a treatment-specific enhancer of outcome for the D-cycloserine group only. At posttreatment, the D-cycloserine group had the lowest cortisol reactivity and smallest startle response during virtual reality scenes. CONCLUSIONS: A six-session virtual reality treatment was associated with reduction in PTSD diagnoses and symptoms in Iraq and Afghanistan veterans, although there was no control condition for the virtual reality exposure. There was no advantage of D-cycloserine for PTSD symptoms in primary analyses. In secondary analyses, alprazolam impaired recovery and D-cycloserine enhanced virtual reality outcome in patients who demonstrated within-session learning. D-cycloserine augmentation reduced cortisol and startle reactivity more than did alprazolam or placebo, findings that are consistent with those in the animal literature.
RCT Entities:
OBJECTIVE: The authors examined the effectiveness of virtual reality exposure augmented with D-cycloserine or alprazolam, compared with placebo, in reducing posttraumatic stress disorder (PTSD) due to military trauma. METHOD: After an introductory session, five sessions of virtual reality exposure were augmented with D-cycloserine (50 mg) or alprazolam (0.25 mg) in a double-blind, placebo-controlled randomized clinical trial for 156 Iraq and Afghanistan war veterans with PTSD. RESULTS:PTSD symptoms significantly improved from pre- to posttreatment across all conditions and were maintained at 3, 6, and 12 months. There were no overall differences in symptoms between D-cycloserine and placebo at any time. Alprazolam and placebo differed significantly on the Clinician-Administered PTSD Scale score at posttreatment and PTSD diagnosis at 3 months posttreatment; the alprazolam group showed a higher rate of PTSD (82.8%) than the placebo group (47.8%). Between-session extinction learning was a treatment-specific enhancer of outcome for the D-cycloserine group only. At posttreatment, the D-cycloserine group had the lowest cortisol reactivity and smallest startle response during virtual reality scenes. CONCLUSIONS: A six-session virtual reality treatment was associated with reduction in PTSD diagnoses and symptoms in Iraq and Afghanistan veterans, although there was no control condition for the virtual reality exposure. There was no advantage of D-cycloserine for PTSD symptoms in primary analyses. In secondary analyses, alprazolam impaired recovery and D-cycloserine enhanced virtual reality outcome in patients who demonstrated within-session learning. D-cycloserine augmentation reduced cortisol and startle reactivity more than did alprazolam or placebo, findings that are consistent with those in the animal literature.
Authors: Eric Vermetten; Meena Vythilingam; Christian Schmahl; Carien DE Kloet; Steven M Southwick; Dennis S Charney; J Douglas Bremner Journal: Ann N Y Acad Sci Date: 2006-07 Impact factor: 5.691
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Adam J Guastella; Rick Richardson; Peter F Lovibond; Ronald M Rapee; Jonathan E Gaston; Philip Mitchell; Mark R Dadds Journal: Biol Psychiatry Date: 2008-01-07 Impact factor: 13.382
Authors: Michael W Otto; David F Tolin; Naomi M Simon; Godfrey D Pearlson; Shawnee Basden; Suzanne A Meunier; Stefan G Hofmann; Katherine Eisenmenger; John H Krystal; Mark H Pollack Journal: Biol Psychiatry Date: 2009-10-06 Impact factor: 13.382
Authors: Matt G Kushner; Suck Won Kim; Christopher Donahue; Paul Thuras; David Adson; Michael Kotlyar; James McCabe; Jillian Peterson; Edna B Foa Journal: Biol Psychiatry Date: 2007-06-22 Impact factor: 13.382
Authors: Sabine Wilhelm; Ulrike Buhlmann; David F Tolin; Suzanne A Meunier; Godfrey D Pearlson; Hannah E Reese; Paul Cannistraro; Michael A Jenike; Scott L Rauch Journal: Am J Psychiatry Date: 2008-02-01 Impact factor: 18.112
Authors: Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack Journal: Biol Psychiatry Date: 2015-09-25 Impact factor: 13.382
Authors: Tanja Jovanovic; Erica J Duncan; Joanna Kaye; Kristie Garza; Seth D Norrholm; Sabra S Inslicht; Thomas C Neylan; Sanjay J Mathew; Dan Iosifescu; Barbara O Rothbaum; Helen S Mayberg; Boadie W Dunlop Journal: Psychophysiology Date: 2019-02-26 Impact factor: 4.016
Authors: Matthew J Girgenti; Sriparna Ghosal; Dora LoPresto; Jane R Taylor; Ronald S Duman Journal: Neurobiol Dis Date: 2016-12-30 Impact factor: 5.996
Authors: Joseph F McGuire; Scott P Orr; Joey K-Y Essoe; James T McCracken; Eric A Storch; John Piacentini Journal: Expert Rev Neurother Date: 2016-06-27 Impact factor: 4.618
Authors: Jessica L Maples-Keller; Brian E Bunnell; Sae-Jin Kim; Barbara O Rothbaum Journal: Harv Rev Psychiatry Date: 2017 May/Jun Impact factor: 3.732